Your browser doesn't support javascript.
loading
A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients.
Zhang, Yin-Jie; Yang, Yang; Wei, Qing; Xu, Ting; Zhang, Xiao-Tian; Gao, Jing; Tan, Si-Yi; Liu, Bao-Rui; Zhang, Jing-Dong; Chen, Xiao-Bing; Wang, Zhao-Jie; Qiu, Meng; Wang, Xin; Shen, Lin; Wang, Xi-Cheng.
Afiliación
  • Zhang YJ; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, P. R. China.
  • Yang Y; Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P. R. China.
  • Wei Q; Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, P. R. China.
  • Xu T; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, P. R. China.
  • Zhang XT; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.
  • Gao J; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, P. R. China.
  • Tan SY; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, P. R. China.
  • Liu BR; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, P. R. China.
  • Zhang JD; Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, P. R. China.
  • Chen XB; Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, P. R. China.
  • Wang ZJ; Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.
  • Qiu M; Department of Gastroenterology and Medical Oncology, Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou, Henan, P. R. China.
  • Wang X; Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, Henan, P. R. China.
  • Shen L; Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, P. R. China.
  • Wang XC; State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Disease, Fourth Military Medical University, Xi'an, Shaanxi, P. R. China.
Gastroenterol Rep (Oxf) ; 9(4): 339-349, 2021 Aug.
Article en En | MEDLINE | ID: mdl-34567566
ABSTRACT

BACKGROUND:

Approximately 10% of patients with gastric cancer (GC) have a genetic predisposition toward the disease. However, there is scant knowledge regarding germline mutations in predisposing genes in the Chinese GC population. This study aimed to determine the spectrum and distribution of predisposing gene mutations among Chinese GC patients known to have hereditary high-risk factors for cancer.

METHODS:

A total of 40 GC patients from 40 families were recruited from seven medical institutions in China. Next-generation sequencing was performed on 171 genes associated with cancer predisposition. For probands carrying pathogenic/likely pathogenic germline variants, Sanger sequencing was applied to validate the variants in the probands as well as their relatives.

RESULTS:

According to sequencing results, 25.0% (10/40) of the patients carried a combined total of 10 pathogenic or likely pathogenic germline variants involving nine different genes CDH1 (n = 1), MLH1 (n = 1), MSH2 (n = 1), CHEK2 (n = 1), BLM (n = 1), EXT2 (n = 1), PALB2 (n = 1), ERCC2 (n = 1), and SPINK1 (n = 2). In addition, 129 variants of uncertain significance were identified in 27 patients.

CONCLUSIONS:

This study indicates that approximately one in every four Chinese GC patients with hereditary high risk factors may harbor pathogenic/likely pathogenic germline alterations in cancer-susceptibility genes. The results further indicate a unique genetic background for GC among Chinese patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Gastroenterol Rep (Oxf) Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Gastroenterol Rep (Oxf) Año: 2021 Tipo del documento: Article
...